CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 48 enrolled
Drug / intervention
LY2216684 +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01263197
NCT01263197Phase 1Completed

Effect of LY2216684 on Heart Rate and Blood Pressure in Healthy Subjects Receiving Oral Doses of Albuterol or Propranolol

Eli Lilly and Company·interventional·Posted Dec 20, 2010·Updated Jan 29, 2019

In Brief

A Phase 1 clinical trial evaluating LY2216684, albuterol, and 4 other interventions for Major Depressive Disorder. Completed, enrolled 48 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the effect of LY2216684 on heart rate of participants receiving Albuterol and Propranolol. Information about any side effects that may occur will also be collected.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 20, 2010
Enrollment StartDec 1, 2010
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.5 years ago

Interventions

LY2216684drug

administered orally

albuteroldrug

administered orally

propranololdrug

administered orally

placebo for LY2216684drug

administered orally

placebo for albuteroldrug

administered orally

placebo for propranololdrug

administered orally